How to Keep Science Moving When Budgets Tighten

Connect with Brandon:   / brandon-farmer-b9b97230  
Connect with Pete:   / ptortorelli  
Connect with Bill:   / founderandcdo  

When budgets tighten, your science shouldn’t grind to a halt.

In this episode of Omni Pod, Bill Schick, Fractional CMO for Omni International, a Revvity brand sits down with Brandon Farmer (Account Executive, Blue Street Capital) and Pete Tortorelli (GM / Managing Director, Revvity Omni International) to get brutally honest about money: frozen grants, squeezed capital budgets, end-of-year “use it or lose it” pressure—and how smart financing keeps critical equipment and research moving anyway.

Learn how labs are acquiring Omni systems without blowing up this year’s budget:
https://omni-inc.com

We dig into real-world stories where six-figure instrument purchases felt impossible on paper—until they were broken into manageable monthly or annual payments—and how labs can use programs like Section 179 and the current “big beautiful bill” window to write off up to $2.5M in equipment while still protecting cash flow.

Pete brings the view from the bench and the boardroom: sample prep bottlenecks, staff cuts, and why automation and bead-mill homogenization become non-negotiable when people and budgets are both stretched thin.

What you’ll learn:
Why “we don’t have budget this year” is often a framing problem—not a dead end
How labs are turning $100K–$300K+ equipment decisions into predictable monthly or annual payments
Practical examples of using financing, leasing, and deferrals to install Omni systems before the first payment hits
How Section 179 and current 2025 incentives can dramatically reduce the real cost of new equipment
Ways to use end-of-year “use it or lose it” funds as leverage instead of wasting them on low-impact spend
What happens to throughput, variability, and timelines when sample prep moves from manual to automated (with actual customer stories)
Common misconceptions about financing (rates, speed, “we don’t finance in academia/BigCo/startups”) and what’s actually true
A simple starting point: the minimum info you need to explore financing for an Omni instrument

Who this is for:
Lab directors, PIs, founders, CFOs, and operations leaders in biotech, pharma, CROs, and core labs who know their sample prep and automation stack is holding them back—but are running into budget constraints, grant uncertainty, or internal resistance to capital spend.
Subscribe for more practical, no-BS conversations on building faster, cleaner, and more resilient preclinical workflows—and drop your questions in the comments so we can tackle your specific budget and equipment challenges next.

https://omni-inc.com
https://omni-inc.com/bead-ruptor-elite
https://omni-inc.com/lh-96-automated-...

Keywords: lab financing, equipment leasing, capital budgeting, Section 179, sample preparation, homogenization, bead milling, automation, preclinical research, laboratory efficiency, Omni International, Revvity, Blue Street Capital, Bead Ruptor, LH 96, use it or lose it budget, ROI, cash flow, CapEx, OpEx.

#SamplePrep #LabFinancing #LifeScienceTools #Homogenization #BeadMilling #LabEfficiency #Section179 #Biotech #OmniInternational #Revvity #BlueStreetCapital #PreclinicalResearch